Investigation of Drug–Polymer Miscibility and Solubilization on Meloxicam Binary Solid Dispersion

  • Xiangjun ShiEmail author
  • Wan Huang
  • Tiantian Xu
  • Baibai Fan
  • Xiaoxia Sheng
Original Article



This work aims to study the solubilizing capacity of solid dispersion technology with three kinds of polymers and explore the factors affecting the dissolution and stability of solid dispersions from drug–polymer miscibility, phase solubility, and crystallization inhibition.


A meloxicam (MLX) solid dispersion was prepared via the solvent evaporation method with polyvinylpyrrolidone (PVP) K30, polyvinylpyrrolidone-co-vinyl acetate (PVP VA) 6:4 and Soluplus® (SLP), respectively. The drug–polymer miscibility, phase solubility, and precipitation study were applied to evaluate the effect of polymers. And the solubility, dissolution behavior, stability, and pharmacokinetic profile of MLX solid dispersion were researched.


The PVP K30, PVP VA, and SLP were found to be miscible with MLX in an increasing order of SLP < PVP K30 < PVP VA, and the dissolution behavior of MLX was improved significantly. According to the phase solubility and the saturation solubility results, the PVP K30 had inferior solubilization capacity to MLX. Moreover, because of MLX crystal precipitation (after 43 ± 7.06 min) in the PVP K30 solution, the relatively short supersaturation time was demonstrated by precipitation study. In comparison, PVP VA and SLP had better performance to improve solubility and inhibit crystallization. The stability experiment results indicated that MLX-PVP K30 and MLX-SLP appeared evident crystallization and poor dissolution rate, whereas, the MLX-PVP VA was comparatively stable. In addition, the pharmacokinetics study of MLX-PVP VA showed larger Cmax (3.25 times) and AUC (2.88 times) than pure MLX.


This study demonstrated enhancement in solubility and dissolution behavior of MLX, via solid dispersion technology. The well solubility and storage stability of MLX-PVP VA (1:5, w/w) were expected to develop a new oral pharmaceutical product. Besides, in the current study, the drug–polymer miscibility, solubilizing capacity, and inhibition ability of the polymer were systematically discussed. The results indicated that above aspects have positive effects on the screening of polymers for amorphous solid dispersion.


Meloxicam Amorphous solid dispersion Dissolution Miscibility Precipitation inhibition Stability 



High acknowledgments are given to Lin Yang, Fuqi Fei, and Yuzhi Wang (Zhejiang University of Technology) for assisting pharmacokinetic study.

Funding information

This work was funded by Project 21606203 of the Natural Science Foundation of China.

Compliance with Ethical Standards

The experimental protocols of the animal studies followed the Animal Ethics Committee of Zhejiang University of Technology. And all operations involving animals were conducted with the guidelines of the National Institutes of Health Guide for Care and Use of Laboratory Animals.

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. 1.
    Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012;2012:195727.Google Scholar
  2. 2.
    Sawicki E, Schellens JHM, Beijnen JH, Nuijen B. Inventory of oral anticancer agents: pharmaceutical formulation aspects with focus on the solid dispersion technique. Cancer Treat Rev. 2016;50:247–63.Google Scholar
  3. 3.
    Bandari S, Jadav S, Eedara BB, Dhurke R, Jukanti R. Enhancement of solubility and dissolution rate of loratadine with Gelucire 50/13. J Pharm Innov. 2014;9(2):141–9.Google Scholar
  4. 4.
    Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12(23):1068–75.Google Scholar
  5. 5.
    Graeser KA, Patterson JE, Zeitler JA, Rades T. The role of configurational entropy in amorphous systems. Pharmaceutics. 2010;2(2):224–44.Google Scholar
  6. 6.
    Augustijns P, Brewster ME. Supersaturating drug delivery systems: fast is not necessarily good enough. J Pharm Sci. 2012;101(1):7–9.Google Scholar
  7. 7.
    Bavishi DD, Borkhataria CH. Spring and parachute: how cocrystals enhance solubility. Prog Cryst Growth Charact Mater. 2016;62(3):1–8.Google Scholar
  8. 8.
    Babu NJ, Nangia A. Solubility advantage of amorphous drugs and pharmaceutical cocrystals. Cryst Growth Des. 2011;11(7):2662–79.Google Scholar
  9. 9.
    Craye G, Lobmann K, Grohganz H, Rades T, Laitinen R. Characterization of amorphous and co-amorphous simvastatin formulations prepared by spray drying. Molecules. 2015;20(12):21532–48.Google Scholar
  10. 10.
    DeBoyace K, Wildfong PLD. The application of modeling and prediction to the formation and stability of amorphous solid dispersions. J Pharm Sci. 2018;107(1):57–74.Google Scholar
  11. 11.
    Takeuchi I, Otsuki M, Kuroda H, Makino K. Estimation of crystallinity of indomethacin by usage of terahertz time-domain spectroscopy and calibration curve: correlation between crystallinity and solubility. J Drug Deliv Sci Technol. 2018;45:70–5.Google Scholar
  12. 12.
    Prudic A, Ji Y, Luebbert C, Sadowski G. Influence of humidity on the phase behavior of API/polymer formulations. Eur J Pharm Biopharm. 2015;94:352–62.Google Scholar
  13. 13.
    Chen H, Pui Y, Liu C, Chen Z, Su CC, Hageman M, et al. Moisture-induced amorphous phase separation of amorphous solid dispersions: molecular mechanism, microstructure, and its impact on dissolution performance. J Pharm Sci. 2018;107(1):317–26.Google Scholar
  14. 14.
    Alfred CFR, Taylor LS. Effect of polymer hygroscopicity on the phase behavior of amorphous solid dispersions in the presence of moisture. Mol Pharm. 2009;7(2):477–90.Google Scholar
  15. 15.
    Ghareeb MM, Abdulrasool AA, Hussein AA, Noordin MI. Kneading technique for preparation of binary solid dispersion of meloxicam with poloxamer 188. AAPS PharmSciTech. 2009;10(4):1206–15.Google Scholar
  16. 16.
    Aboelwafa AA, Fahmy RH. A pilot human pharmacokinetic study and influence of formulation factors on orodispersible tablet incorporating meloxicam solid dispersion using factorial design. Pharm Dev Technol. 2012;17(1):1–14.Google Scholar
  17. 17.
    Caron V, Tajber L, Corrigan OI, Healy AM. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone. Mol Pharm. 2011;8(2):532–42.Google Scholar
  18. 18.
    Davis MT, Egan DP, Kuhs M, Albadarin AB, Griffin CS, Collins JA, et al. Amorphous solid dispersions of BCS class II drugs: a rational approach to solvent and polymer selection. Chem Eng Res Des. 2016;110:192–9.Google Scholar
  19. 19.
    Marsac PJ, Shamblin SL, Taylor LS. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm Res. 2006;23(10):2417–26.Google Scholar
  20. 20.
    Thakral S, Thakral NK. Prediction of drug-polymer miscibility through the use of solubility parameter based Flory-Huggins interaction parameter and the experimental validation: PEG as model polymer. J Pharm Sci. 2013;102(7):2254–63.Google Scholar
  21. 21.
    Yani Y, Kanaujia P, Chow PS, Tan RBH. Effect of API-polymer miscibility and interaction on the stabilization of amorphous solid dispersion: a molecular simulation study. Ind Eng Chem Res. 2017;56(44):12698–707.Google Scholar
  22. 22.
    Djuris J, Nikolakakis I, Ibric S, Djuric Z, Kachrimanis K. Preparation of carbamazepine-Soluplus solid dispersions by hot-melt extrusion, and prediction of drug-polymer miscibility by thermodynamic model fitting. Eur J Pharm Biopharm. 2013;84(1):228–37.Google Scholar
  23. 23.
    Verma S, Rudraraju VS. A systematic approach to design and prepare solid dispersions of poorly water-soluble drug. AAPS PharmSciTech. 2014;15(3):641–57.Google Scholar
  24. 24.
    Tian Y, Caron V, Jones DS, Healy AM, Andrews GP. Using Flory-Huggins phase diagrams as a pre-formulation tool for the production of amorphous solid dispersions: a comparison between hot-melt extrusion and spray drying. J Pharm Pharmacol. 2014;66(2):256–74.Google Scholar
  25. 25.
    Just S, Sievert F, Thommes M, Breitkreutz J. Improved group contribution parameter set for the application of solubility parameters to melt extrusion. Eur J Pharm Biopharm. 2013;85(3 Pt B):1191–9.Google Scholar
  26. 26.
    Pina MF, Zhao M, Pinto JF, Sousa JJ, Craig DQM. The influence of drug physical state on the dissolution enhancement of solid dispersions prepared via hot-melt extrusion: a case study using olanzapine. J Pharm Sci. 2014;103(4):1214–23.Google Scholar
  27. 27.
    Luger P, Daneck K, Engel W, Trummlitz G, Wagner K. Structure and physicochemical properties of meloxicam, a new NSAID. Eur J Pharm Sci. 1996;4(3):175–87.Google Scholar
  28. 28.
    Aoki T, Yamaguchi H, Naito H, Shiiki K, Izawa K, Ota Y, et al. Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery. Int J Oral Maxillofac Surg. 2006;35(7):613–7.Google Scholar
  29. 29.
    Al-Remawi M, Ali AMA, Khames A, Hamaidi M. Meloxicam-paracetamol binary solid dispersion systems with enhanced solubility and dissolution rate: preparation, characterization, and in vivo evaluation. J Pharm Innov. 2017;12(3):206–15.Google Scholar
  30. 30.
    Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world’s top oral drugs. AAPS J. 2009;11(4):740–6.Google Scholar
  31. 31.
    Seedher N, Bhatia S. Solubility enhancement of cox-2 inhibitors using various solvent systems. AAPS PharmSciTech. 2003;4(3):36–44.Google Scholar
  32. 32.
    Haser A, Huang S, Listro T, White D, Zhang F. An approach for chemical stability during melt extrusion of a drug substance with a high melting point. Int J Pharm. 2017;524(1–2):55–64.Google Scholar
  33. 33.
    LaFountaine JS, McGinity JW, Williams RO 3rd. Challenges and strategies in thermal processing of amorphous solid dispersions: a review. AAPS PharmSciTech. 2016;17(1):43–55.Google Scholar
  34. 34.
    Haser A, Cao T, Lubach JW, Zhang F. In situ salt formation during melt extrusion for improved chemical stability and dissolution performance of a meloxicam-copovidone amorphous solid dispersion. Mol Pharm. 2018;15(3):1226–37.Google Scholar
  35. 35.
    Hansen CM. Hansen solubility parameters: a user’s handbook. 2nd ed. London: CRC Press; 2007. p. 1–24.Google Scholar
  36. 36.
    Higuchi T, Connors KA. Phase solubility techniques. In: Reilly CN, editor. Advances in analytical chemistry and instrumentation. New York: Wiley-Interscience;1965;4:117–12.Google Scholar
  37. 37.
    Greenhalgh DJ, Williams AC, Timmins P, York P. Solubility parameters as predictors of miscibility in solid dispersions. J Pharm Sci. 1999;88(11):1182–90.Google Scholar
  38. 38.
    Hurley D, Potter CB, Walker GM, Higginbotham CL. Investigation of ethylene oxide-co-propylene oxide for dissolution enhancement of hot-melt extruded solid dispersions. J Pharm Sci. 2018;107(5):1372–82.Google Scholar
  39. 39.
    Piel G, Moutard S, Perly B, Henry De Hassonville S, Bertholet P, Barillaro V, et al. Comparison of two methods currently used to determine the interaction between cyclodextrins and drugs: phase solubility diagrams and NMR spectroscopy. J Drug Deliv Sci Technol. 2004;14(1):87–91.Google Scholar
  40. 40.
    Sapte S, Pore Y. Inclusion complexes of cefuroxime axetil with beta-cyclodextrin: physicochemical characterization, molecular modeling and effect of l-arginine on complexation. J Pharm Anal. 2016;6(5):300–6.Google Scholar
  41. 41.
    Shah M, Karekar P, Sancheti P, Vyas V, Pore Y. Effect of PVP K30 and/or l-arginine on stability constant of etoricoxib–HPβCD inclusion complex: preparation and characterization of etoricoxib–HPβCD binary system. Drug Dev Ind Pharm. 2009;35(1):118–29.Google Scholar
  42. 42.
    Chauhan H, Kuldipkumar A, Barder T, Medek A, Gu CH, Atef E. Correlation of inhibitory effects of polymers on indomethacin precipitation in solution and amorphous solid crystallization based on molecular interaction. Pharm Res. 2014;31(2):500–15.Google Scholar
  43. 43.
    Sharma S, Sher P, Badve S, Pawar AP. Adsorption of meloxicam on porous calcium silicate: characterization and tablet formulation. AAPS PharmSciTech. 2005;6(4):E618–E25.Google Scholar
  44. 44.
    Guzmán HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR, et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci. 2007;96(10):2686–702.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Collaborative Innovation Center of Yangtze River Delta Region Green PharmaceuticalsZhejiang University of TechnologyHangzhouPeople’s Republic of China
  2. 2.SoliPharma Sci-Tech Co., Ltd.HangzhouPeople’s Republic of China

Personalised recommendations